Protagenic Therapeutics I...

NASDAQ: PTIX · Real-Time Price · USD
2.92
-0.15 (-4.89%)
At close: Aug 15, 2025, 3:59 PM
2.88
-1.41%
After-hours: Aug 15, 2025, 07:55 PM EDT

Protagenic Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
12.57K 25.14K n/a n/a n/a n/a 1.42K 91.00 n/a n/a n/a n/a n/a n/a n/a n/a n/a
Gross Profit
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Income
-1.45M -1.64M -652K -1.67M -1.74M -1.21M -1.43M -1.14M -739K -656K -924K -637K -1.34M -861K -764K -1.31M -1.21M
Interest Income
8.1K 9.03K 11.28K 9.29K 13.87K 53.66K 69.22K 84.71K 56.89K 92.43K 42.5K 32.9K 17.97K 32.64K 336.00 227.00 5.00
Pretax Income
-1.44M -1.55M -641K -1.61M -1.72M -1.68M -1.4M -1.21M -718K -601K -925K -667K -1.36M -890K -878K -1.55M -1.21M
Net Income
-1.44M -1.55M -641K -1.61M -1.72M -1.68M -1.4M -1.21M -718K -607K -895K -667K -1.35M -890K -878K -1.55M -1.21M
Selling & General & Admin
567.74K 739.82K 287.88K 453.3K 277.61K 200.8K 307.68K 307.36K 391.26K 398.26K 422.69K 476.16K 671.44K 714.65K 506.89K 1.17M 613.84K
Research & Development
880.37K 806K 364.18K 1.21M 1.46M 1.01M 1.12M 836.38K 348.03K 257.52K 501.37K 160.51K 669.84K 146.57K 257.28K 140.59K 592.35K
Other Expenses
n/a 0.00 n/a n/a n/a n/a n/a -0.00 n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
1.45M 1.64M 652.07K 1.67M 1.74M 1.21M 1.43M 1.14M 739.29K 655.78K 924.06K 636.67K 1.34M 861.22K 764.17K 1.31M 1.21M
Interest Expense
n/a n/a n/a n/a n/a 12.85K 31.96K 31.61K 31.26K 31.96K 31.96K 39.7K 33.84K 59.32K 114.46K 239.19K 83.94K
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
1.45M 1.64M 652.07K 1.67M 1.74M 1.21M 1.43M 1.14M 739.29K 655.78K 924.06K 636.67K 1.34M 861.22K 764.17K 1.31M 1.21M
Income Tax Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a 6.04K -30.71K n/a -13.01K n/a -336 -227 n/a
Shares Outstanding (Basic)
523.18K 6.5M 4.47M 4.44M 4.43M 4.38M 4.33M 4.33M 4.22M 4.32M 4.32M 4.32M 4.31M 4.13M 4.13M 3.62M 2.63M
Shares Outstanding (Diluted)
523.18K 6.5M 4.47M 4.44M 4.43M 4.38M 4.33M 4.33M 4.32M 4.32M 4.32M 4.32M 4.31M 4.13M 4.13M 3.62M 2.63M
EPS (Basic)
-2.75 -0.33 -0.14 -0.36 -0.39 -0.38 -0.32 -0.28 -0.17 -0.14 -0.21 -0.15 -0.32 -0.22 -0.2 -0.44 -0.44
EPS (Diluted)
-2.75 -0.33 -0.14 -0.36 -5.44 -0.38 -0.32 -0.28 -0.17 -0.14 -0.21 -0.15 -0.32 -0.22 -0.2 -0.44 -0.44
EBITDA
-1.44M -1.54M -628K -1.59M -1.73M -1.64M -1.36M -1.18M -687K -569K -893K -627K -1.33M -831K -764K -1.31M -1.12M
EBIT
-1.45M -1.55M -641K -1.61M -1.74M -1.64M -1.36M -1.18M -687K -569K -893K -627K -1.33M -831K -764K -1.31M -1.12M
Depreciation & Amortization
12.57K 12.57K 12.57K 12.57K 12.57K 26.62K 1.42K 91.00 90.00 30.00 924.06K 636.67K 1.34M 72.00 72.00 72.00 72.00